Alterity Therapeutics (ATHE)

• Market cap: $19.2M
• 1 day: 4.76%
• 5 days: -8.33%
• 1 month: 109.52%
• 3 months: 78.86%
• 6 months: 24.29%
• Year to date: -11.29%
• 1 year: -17.29%
• 5 years: -77.13%
• 10 years: -97.99%

About: Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Employees: 10

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

20% more funds holding

Funds holding: 10 [Q2] → 12 (+2) [Q3]

0% less ownership

Funds ownership: 0% [Q2] → 0% (-0%) [Q3]

35% less capital invested

Capital invested by funds: $229K [Q2] → $149K (-$79.9K) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8 264% upside
• Avg. target: $8 264% upside
• High target: $8 264% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 26% 1-year accuracy 7 / 27 met price target

264% upside $8

Buy Initiated

12 Dec 2024